Metabolic Diseases and Diabetes
In partnership with the IGSB, Mark Ratain, MD (Department of Medicine, Section of Hematology / Oncology) and colleagues are analyzing genome wide variation in DNA sequence and gene expression in a large collection of human livers to discover patterns of genomic variation and expression. This comprehensive study, never before conducted, will provide the basis for evaluating potential outcomes of drug therapy in individual cancer patients.
About 75% of the top 200 drugs prescribed are eliminated from the body through the metabolic enzymes in the liver. In addition to receiving seed funding as part of the IGSB Metabolic Diseases and Diabetes Initiative, Ratain and colleagues are using the resources of the High Throughput Genome Analysis Core (HGAC) to perform their study.
As part of the same Initiative, Chris Rhodes, PhD (Department of Medicine, Section of Endocrinology, Diabetes and Metabolism) is performing drug and genome screening of insulin-secreting cells in the Celluar Screening Center (CSC) to identify therapies which promote insulin production in diabetes patients.
- Profiling Reactive Metabolites via Chemical Trapping and Targeted Mass Spectrometry
- Does the brain listen to the gut?
- (Meta)genomic insights into the pathogenome of Cellulosimicrobium cellulans
- A robust adaptive denoising framework for real-time artifact removal in scalp EEG measurements
- Imputing Gene Expression in Uncollected Tissues Within and Beyond GTEx
- Small Rad51 and Dmc1 Complexes Often Co-occupy Both Ends of a Meiotic DNA Double Strand Break
- Controlling the Cyanobacterial Clock by Synthetically Rewiring Metabolism
- Choosing experiments to accelerate collective discovery
- The transcriptional landscape of age in human peripheral blood
- Digital signaling decouples activation probability and population heterogeneity